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ABSTRACT
Aims. Genetic determinants of variability in response to b-blockers are poorly characterized. We deﬁned changes
in mRNA expression after a b-blocker to identify novel genes that could affect response and correlated these with
inhibition of exercise-induced tachycardia, a measure of b-blocker sensitivity.
Methods. Nine subjects exercised before and after a single oral dose of 25mg atenolol and mRNA gene expression
was measured using an Affymetrix GeneChip Human Gene 1.0 ST Array. The area under the heart rate-exercise
intensity curve (AUC) was calculated for each subject; the difference between post- and pre-atenolol AUCs (D AUC),
a measure of b-blocker response, was correlated with the fold-change in mRNA expression of the genes that changed
more than 1.3-fold.
Results. Fifty genes showed more than 1.3-fold increase in expression; 9 of these reached statistical signiﬁcance
(P < 0.05). Thirty-six genes had more than 1.3-fold decrease in expression after atenolol; 6 of these reached statistical
signiﬁcance (P < 0.05). Change in mRNA expression of FGFBP2 and Probeset ID 8118979 was signiﬁcantly
correlated with atenolol response (P = 0.03 and 0.02, respectively).
Conclusion. The expression of several genes not previously identiﬁed as part of the adrenergic signaling pathway
changed in response to a single oral dose of atenolol. Variation in these genes could contribute to unexplained
differences in response to b-blockers.
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eta-blockers are frequently prescribed to
treat ischemic heart disease, heart failure,
hypertension, and arrhythmias [1–5]. They block
the effects of agonists acting on b-adrenergic
receptors (ARs) and inﬂuence downstream signal-
ing pathways. There are substantial interindi-
vidual and ethnic differences in response to
b-blockers that are partly accounted for by varia-
tion in the genes encoding the b1-AR (ADRB1)
and mediators of downstream signaling pathways
[6,7]. The relationship between variability in
ADRB1 and other candidate genes and variability
in response to b-blockers has been extensively
evaluated [6,8], but much of the variability
remains unexplained.
Another approach to identifying the mecha-
nisms underlying interindividual variability in
response would be to identify additional candidate
41
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RNA (mRNA) that occur after exposure to a
b-blocker. There is no information regarding such
an approach.
Therefore, we carried out this exploratory study
to identify novel genes that may regulate response
to a b-blocker by measuring changes in mRNA
expression after oral administration of a b-blocker
(atenolol) to subjects who underwent an exercise
test to determine b-blocker sensitivity. We also
studied the correlation between change in mRNA
expression after atenolol administration and




This study was approved by the Institutional
Review Board of Vanderbilt University Medical
Centre, Nashville, TN, and all subjects gave
written informed consent. We enrolled 9 unre-
lated subjects; one subject was excluded from
analysis because the post-treatment sample could
not be hybridized. Subjects were eligible to par-
ticipate if they were between 18–40 years of age
and had no clinically signiﬁcant abnormality based
on medical history, physical examination, electro-
cardiogram, and routine laboratory testing. Sub-
jects reported their ethnicity and that of their
parents and grandparents using checkboxes to
choose among “Caucasian”, “African–American”,
“Hispanic”, “Chinese”, “Japanese”, and “other”
(the latter to be speciﬁed). Multiple choices were
permitted. A patient was assigned to an ethnic
group when both parents and at least three out of
four grandparents were of the same ethnicity.
Patients were free of medications and dietary
supplements for at least 1 week and received a
controlled alcohol-free and caffeine-free diet (pro-
viding 150 mmol of sodium, 70 mmol of potas-
sium, and 600 mmol of calcium daily) for 5 days
before the study.
Protocol
Details of the exercise protocol have been
described in detail elsewhere [6]. Brieﬂy, after an
overnight fast a 20 G intravenous cannula was
inserted into an antecubital arm vein for blood
sampling and after 30 minutes of supine rest, a
baseline blood sample was drawn for mRNA
analysis into two PAXgene Blood mRNA Tubes
(PreAnalytiX/Qiagen Inc., Valencia, CA), incu-
bated at room temperature for 2 hours, and then
stored at -20°C. Then, subjects exercised on an
electronically braked supine bicycle ergometer at
sequentially increasing workloads of 25, 50, and 75
watts for 2 minutes each. Then, 10 minutes after
completion of exercise, subjects swallowed a 25 mg
tablet of atenolol. A second blood sample for
mRNA expression was collected 2.5 hours after
atenolol (to coincide with peak atenolol concen-
trations) and immediately after the blood draw a





and then subjected to DNase treatment according
to the manufacturer’s instructions (Qiagen, Valen-
cia, CA). The mRNA were assessed for concentra-
tion by spectrophotometry and integrity using the
Agilent Bioanalyzer (Agilent Technologies, Palo
Alto, CA), and then stored at -20°C.
Microarray
Following quality control, the mRNA was pre-
pared for microarray analysis using the GeneChip
Whole Transcript (WT) Sense Target Labeling
Assay protocol (Affymetrix Inc, Santa Clara, CA).
Brieﬂy, a total of 100ng of total mRNA was reverse
transcribed to cDNA T7-random primers fol-
lowed by second-strand synthesis. The double-
stranded cDNA was then used as template in an
in vitro transcription reaction followed by cDNA
synthesis, fragmentation of the single stranded
cDNA and labeling through a terminal deoxy-
transferase reaction. The biotinylated cDNA
(5 mg) was fragmented and hybridized to an
Affymetrix GeneChip Human Gene 1.0 ST Array
(Affymetrix Inc, Santa Clara, CA).
Data Analysis
Following scanning, CEL ﬁles were imported into
Partek Genomic Suitev6.4 (Partek Inc, St Louis,
MO) and robust multi-chip average (RMA) nor-
malized. A paired-sample t-test was performed
between the pre-treatment and post-treatment
groups. A 1.3-fold change in gene expression was
considered potentially signiﬁcant [10].
Demographic data are expressed as
mean  standard deviation (SD). We used two-
sample Wilcoxon rank-sum (Mann-Whitney) test
to compare outcomes before and after atenolol. A
response-feature approach was used to model mul-
tiple heart rate measurements in the same subjects
42 Kohli et al.
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the area under the heart rate-exercise intensity
curve (AUC) for each subject. The difference
between post- and pre-atenolol heart rate AUCs
(D AUC) was calculated to determine the response
to atenolol and this was correlated with the fold-
change in mRNA expression of the genes that
were signiﬁcantly upregulated and downregulated
(1.3-fold) using a non-parametric measure of
correlation (Spearman’s rank correlation coefﬁ-
cient). Analyses were performed using the statisti-
cal software STATA v.10.0 (StataCorp, College




The demographic characteristics of the study sub-
jects (n = 8) are described in Table 1.
Atenolol Effect
Atenolol signiﬁcantly reduced the resting heart
rate (mean reduction = 6.5  6.8 beats/minute;
P = 0.02), and heart rate at all the exercise
stages (mean reduction = 13  10.2, 13.1  9.9,
19.0  9.5 beats/minute at 25, 50, and 75W of
exercise, respectively; all P < 0.02). Heart rate-
AUC was also signiﬁcantly reduced (mean reduc-
tion = 1050  658 beats/minute.watt; P = 0.02).
Microarray
There were 50 genes upregulated more that 1.3-
fold (Table 2). Change in mRNA expression for 9
of these genes (TXN, SLCO4C1, LOC339240,
SNRPN, CLEC2B, SNORA49 and Probeset IDs
8142763, 7984008, 7906751) reached statistical
signiﬁcance (P < 0.05) (Figure 1). A range of other
genes including WD repeat domain 74, small cajal
body-speciﬁc mRNA 7, killer cell lectin-like
receptor subfamily F, S100 calcium binding
protein A12, and ﬁbroblast growth factor binding
protein 2 were also upregulated. Change in
mRNA expression for ﬁbroblast growth factor
binding protein 2 (FGFBP2) correlated signiﬁ-
cantly with atenolol effect (D AUC) (Spearman
coefﬁcient =- 0.76; P = 0.03).
Thirty-six genes were downregulated at least
1.3-fold after atenolol administration (Table 3);
the decrease in mRNA expression for 6 of these
Table 1 Demographic characteristics
Characteristic (N = 8) Mean  SD





Weight (kg) 70.5  12.0
Height (m) 1.72  0.08
Figure 1 Signiﬁcantly upregulated
and downregulated genes. Error bars
represent standard error.
Atenolol and Gene Expression 43
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Arch Drug Info 2009;2:41–50genes (FKBP5, SLC6A8 and Probeset IDs
7996260, 8084810, 8003857, 8125461) reached
statistical signiﬁcance (P < 0.05) (Figure 1).
Change in mRNA expression of Probeset ID
8118979 after atenolol administration was signiﬁ-
cantly correlated with the decrease in heart rate
AUC (Spearman correlation coefﬁcient = 0.77;
P = 0.02). Change in mRNA expression for none
of the other upregulated or downregulated genes
correlated signiﬁcantly with attenuation of exer-
cise induced tachycardia.
Discussion
There is no information about the effect of a
b-blocker on mRNA expression, thus our ﬁnding
that several genes are upregulated or downregu-
lated are of interest. There are 50 genes upregu-
lated more than 1.3-fold, and change in mRNA
expression for 9 of these genes is statistically sig-
niﬁcant (P < 0.05). Many of these genes code for
ribosomal proteins, small nuclear ribonucleopro-
tein polypeptides and signal transduction pathways
that have not previously been associated with
b-blocker signaling. One of the signiﬁcantly
upregulated genes (TXN) codes for thioredoxin.
Thioredoxins act as antioxidants by facilitating the
reduction of other proteins by cysteine thiol-
disulﬁde exchange [12,13]. The thioredoxins are
kept in the reduced state by the ﬂavoenzyme
thioredoxin reductase, in a NADPH-dependent
reaction [14]. Thioredoxin reductase activity is
indirectly regulated by b2-ARs in human cutane-
ous tissue; its activity in human melanoma cells is
stimulated by calcium, and calcium exchange
between these cells and surrounding skin is stimu-
lated by b2-ARs [15]. Another upregulated gene,
SLCO4C1, codes for an organic anion transporter
that is expressed on the basolateral membrane of
renal proximal tubular cells. It transports cardiac
glycosides, thyroid hormone, cAMP, and metho-
trexate in a sodium-independent manner [16].
However, no clear role has been identiﬁed for
these signiﬁcantly upregulated genes in the adren-
ergic signaling pathway.
Similarly, no clear role has been identiﬁed in
adrenergic signaling for other upregulated genes
such as WD repeat domain 74, small cajal body-
speciﬁc mRNA 7, killer cell lectin-like receptor
subfamily F, S100 calcium binding protein A12,
ﬁbroblast growth factor binding protein 2, solute
carrier organic anion transporter family, and
keratin pseudogene.
Thirty-six genes are downregulated at least 1.3-
fold after atenolol administration, and the decrease
in mRNA expression for 6 of these genes (FKBP5,
SLC6A8 and Probeset IDs 7996260, 8084810,
8003857, 8125461) is statistically signiﬁcant.
These genes can be categorized into 3 broad onto-
genic groups based on the proteins that they code:
transport proteins, ion channels and cytoskeletal
proteins. FKBP5 codes for a chaperone protein
that has been implicated in stress related disorders
[16,17]. The other downregulated genes code for a
wide variety of proteins like solute carrier family 4,
anion exchanger, hemoglobin zeta, tripartite
motif-containing 58, and d-aminolevulinate syn-
thase 2. As is the case with the upregulated genes,
the role of these downregulated genes in adrener-
gic signaling is not known
Change in mRNA expression of FGFBP2 and
Probeset ID 8118979 is correlated signiﬁcantly
with the b-blocker effect. The role of these 2 genes
in adrenergic signaling pathway is not known.
However, FGF2 (ﬁbroblast growth factor 2) codes
for a growth factor that is needed for maturation
and survival of catecholaminergic neurons, and
FGFBP codes for a protein that binds extracellular
FGF2 and enhances its activity. Chronic adminis-
tration of antidepressants, which act on nor-
adrenergic pathways, increases the expression of
these two proteins [18]. Expression of FGF2 is
also increased in cardiac myocytes in response
to stimulation of a1-adrenoceptors [19]. Thus,
FGFBP is associated with the adrenergic system,
but its role in cardiac b-adrenergic signaling is not
established.
This study has several limitations. Subjects
exercised before atenolol was administered, and
the effect of atenolol on mRNA expression could
potentially have been altered by the preceding
exercise. However, the majority of genes that
changed more than 1.3-fold were not inﬂuenced
by exercise in previous studies [20–25]. Another
potential limitation is that we used whole blood
for analysis of mRNA expression, and changes in
mRNA expression can be lower than those
obtained from isolated cells [26,27]. We studied
change in mRNA expression 2.5 hours after
administration of a single dose of atenolol, when
peak atenolol concentrations are reached. The
pattern of gene expression after atenolol may vary
with time, and after chronic administration of
drug. However, ethnic and genetic differences in
sensitivity to atenolol measured as inhibition of
exercise-induced tachycardia can be detected 2.5
hours after a single dose [6]. Therefore, the gene
48 Kohli et al.
Arch Drug Info 2009;2:41–50expression proﬁle at this time is of interest. We
administered a single dose of atenolol (25 mg) to
our subjects. It is possible that the change in the
pattern of mRNA expression with higher doses or
with multiple doses may differ. Also, we did not
correct for multiple comparisons but included
only those genes that were upregulated or down-
regulated more than 1.3 fold to limit the false
discovery rate; there is little consensus on the
optimum method of correction for multiple com-
parisons in gene expression assays [28], and the
analysis should be regarded as exploratory and
hypothesis-generating.
In conclusion, in this preliminary study many
genes not known to be involved with adrenergic
signaling were upregulated or downregulated in
response to atenolol. Change in mRNA expres-
sion for 2 of these genes is signiﬁcantly correlated
with atenolol-mediated attenuation of exercise-
induced tachycardia. Additional studies to deter-
mine the reproducibility of the ﬁndings and the
effects of chronic therapy may provide novel
insights into the mechanisms of actions of
b-blockers.
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